Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSL Vifor
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Treatments for non-small cell lung cancer, Pompe disease and two main forms of ANCA-associated vasculitis from Roche, Sanofi and CSL Vifor respectively are to be made available for patients on the National Health Service.
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Group, Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma
- Sanifit Therapeutics S.A.